BioCentury

BioCentury writes strategic analysis of biopharma for people who make decisions about pipelines: regulatory trends, first-in-class approvals, China and deal terms. It publishes daily, and its monthly first-in-class approval tallies and its regulatory reform coverage are distinctive among the industry titles. Access is by subscription, so most of the analysis sits behind a paywall. On OnCo it is listed as a source with the tags source and news, read for the pipeline-level and regulatory view of oncology rather than for individual trial results.